Challenges of Formulating Cannabinoids

Drug Discovery & Development, Emerging Market, Life Sciences,
  • Tuesday, June 04, 2019

The evolution of the cannabis industry in Canada will take a giant leap forward in October 2019 with new product categories becoming available in the market. Large and small companies alike are looking ahead to develop quality products that will exceed the expectations of the consumer. However, there are many challenges in formulating any consumable product and a number that are unique to cannabinoid-containing products. This webinar explores product development challenges that the cannabis industry faces; highlighting the considerations that a product developer must take in order to find solutions to difficulties in Input Materials, Cannabinoid Degradation, Drug Delivery and Designing Meaning Studies to Support Development. Experts in Product Development and Clinical Research from DoseCann and KGK Science will walk you through these topics and answer any questions you may have.

Topics of discussion include: 

  • Assuring quality of input materials
    • Control and standardization of cannabis raw material and extraction
    • Influence of contaminants in ingredients that could impact on the properties and quality of the finished product
  • The risks of cannabinoid degradation
    • Tetrahydrocannabinol (THC) is inherently unstable, and therefore it is important to assess compatibility with ingredients and protection provided by packaging
  • Efficient drug delivery of cannabinoids
    • Cannabinoids are poorly absorbed and highly metabolized. The route of delivery will impact the absorption, speed of action and effective blood levels. Formulation strategies are critical to optimizing drug absorption.
    • Consumer behavior, genetic profile, and many other factors have a significant impact on variability, meaning the response to cannabinoid exposure can be highly individual

Speakers

Christina Woollard, Chief Scientific Officer, Dosecann Cannabis Solutions

After qualifying as a Pharmacist from the University of Wales, Cardiff, Christina did a PhD studying the use of liposomes to deliver gene therapy to the lung. She worked as a Formulation Scientist at Pfizer for 4 years and then joined GW just as the company was starting. She spent 17 years managing the Product Development team and working on multiple cannabinoid projects including Sativex, Epidiolex, injectables, solid oral dosage forms, and THCV products. After leaving GW she worked as a consultant specialising in CMC development and cannabinoid science. She is Chief Scientific Officer for Dosecann, responsible for advising on a portfolio of cannabinoid products and co-ordination of new product development and the R&D plan. Her passion is designing good quality medicines specific to the needs of patients. She is also a keen STEM ambassador particularly to encourage young women’s interest in science.

Message Presenter
http://Dr.%20Mal%20Evans,KGK%20Science

Dr. Mal Evans, Chief Scientific Officer, KGK Science

Dr. Mal Evans is the Chief Scientific Officer at KGK Science. She earned her master’s and doctorate degrees in physiology from the University of Guelph and received her D.V.M with distinction in physiology from the University of Sri Lanka. Dr. Evans pioneered research in chronobiology and her landmark work in this area was the first of its kind in North America. Her studies in this area support research conducted in the US and Europe on the impact of cellular oscillatory systems on the microbiome, cognition, sleep wake rhythms, shift work, chronic disease etc. and overflow into application in the supplement industry.

Dr. Evans contributes her specialized knowledge to dietary supplement research, study design and protocol development, as well, she authors final reports and manuscripts for publication in peer reviewed journals. She brings her experience and knowledge in Evidence-Based Medicine into Evidence-Based Nutrition. Her expertise encompasses research in numerous areas including gut health and the microbiome, weight management, cardiovascular health, cognition, menopause, hypertension, arthritis, digestive health, eye health, vitamin research, women’s and men’s health, oxidative stress, immune function, allergies, satiety, dermatology, bioavailability, and various pre-disease and disease indications.

Message Presenter

Who Should Attend?

Industries:

  • Pharmaceuticals
  • Nutraceuticals
  • Raw Materials

Job Titles:

  • Executives & Directors
  • Regulatory Affairs/Compliance
  • Project Management
  • Clinical Research
  • Marketing
  • Growers
  • Supply Chain
  • Science

What You Will Learn

In this free webinar, attendees will gain insights on: 

  • Assuring quality of input materials
    • Control and standardization of cannabis raw material and extraction
    • Influence of contaminants in ingredients that could impact on the properties and quality of the finished product
  • The risks of cannabinoid degradation
    • Tetrahydrocannabinol (THC) is inherently unstable, and therefore it is important to assess compatibility with ingredients and protection provided by packaging
  • Efficient drug delivery of cannabinoids
    • Cannabinoids are poorly absorbed and highly metabolized. The route of delivery will impact the absorption, speed of action and effective blood levels. Formulation strategies are critical to optimizing drug absorption.
    • Consumer behavior, genetic profile, and many other factors have a significant impact on variability, meaning the response to cannabinoid exposure can be highly individual

Xtalks Partner

KGK Science

As a global Contract Research Organization (CRO), KGK Science performs a productive and pioneering role in the realm of scientific study. For over two decades, it has offered well-designed, customized solutions to each of its clients, consolidating its scientific, clinical, commercial, and regulatory abilities into one full-service package.

Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of thought leaders, KGK remains at the forefront of its industry. And, by seamlessly matching its experience with its drive for innovation, this CRO is able to respond effectively to expanding trade and consumer demands.

Through their multidisciplinary, evidence-based nature, KGK’s human clinical trials advance nutritional knowledge and science. Further, by conducting its business on the basis of quality, reliability, and integrity, KGK is able to maintain fruitful, long-term relationships with its employees, customers, suppliers, and colleagues.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account